Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study.
Brink M, Kahle XU, Vermaat JSP, Zijlstra JM, Chamuleau M, Kersten MJ, Durmaz M, Plattel WJ, Lugtenburg PJ, Stevens W, Mous R, de Vries EGE, van der Poel MWM, Panday PVN, Huls G, van Meerten T, Nijland M. Brink M, et al. Among authors: vermaat jsp. Blood Adv. 2021 Aug 10;5(15):2958-2964. doi: 10.1182/bloodadvances.2021004295. Blood Adv. 2021. PMID: 34338755 Free PMC article.
Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia.
Quinten E, Sepúlveda-Yáñez JH, Koning MT, Eken JA, Pfeifer D, Nteleah V, De Groen RAL, Saravia DA, Knijnenburg J, Stuivenberg-Bleijswijk HE, Pantic M, Agathangelidis A, Keppler-Hafkemeyer A, Van Bergen CAM, Uribe-Paredes R, Stamatopoulos K, Vermaat JSP, Zirlik K, Navarrete MA, Jumaa H, Veelken H. Quinten E, et al. Among authors: vermaat jsp. Haematologica. 2024 Mar 1;109(3):824-834. doi: 10.3324/haematol.2022.282542. Haematologica. 2024. PMID: 37439337 Free PMC article.
Precision medicine in diffuse large B-cell lymphoma: hitting the target.
Vermaat JS, Pals ST, Younes A, Dreyling M, Federico M, Aurer I, Radford J, Kersten MJ; EHA Lymphoma Group, a Scientific Working Group of the European Hematology Association. Vermaat JS, et al. Haematologica. 2015 Aug;100(8):989-93. doi: 10.3324/haematol.2015.128371. Haematologica. 2015. PMID: 26314080 Free PMC article. No abstract available.
High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP. Schrader AMR, et al. Among authors: vermaat jsp. Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. Blood. 2018. PMID: 29514783 Free article. No abstract available.
MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.
Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, Kerver ED, Scheepstra CG, Berenschot H, Deenik W, Wegman J, Broers R, de Boer JD, Nijland M, van Wezel T, Veelken H, Spaargaren M, Cleven AH, Kersten MJ, Pals ST. Vermaat JS, et al. Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020. Haematologica. 2020. PMID: 31123031 Free PMC article.
High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.
Elfrink S, de Winde CM, van den Brand M, Berendsen M, Roemer MGM, Arnold F, Janssen L, van der Schaaf A, Jansen E, Groenen PJTA, Eijkelenboom A, Stevens W, Hess CJ, van Krieken JH, Vermaat JSP, Cleven AHG, de Groen RAL, Neviani V, de Jong D, van Deventer S, Scheijen B, van Spriel AB. Elfrink S, et al. Among authors: vermaat jsp. Blood. 2019 Sep 19;134(12):946-950. doi: 10.1182/blood.2019001185. Epub 2019 Jul 31. Blood. 2019. PMID: 31366619 Free PMC article.
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA. Kalakonda N, et al. Among authors: vermaat jsp. Lancet Haematol. 2020 Jul;7(7):e511-e522. doi: 10.1016/S2352-3026(20)30120-4. Lancet Haematol. 2020. PMID: 32589977 Free article. Clinical Trial.
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ. Chamuleau MED, et al. Among authors: vermaat jsp. Haematologica. 2020 Dec 1;105(12):2805-2812. doi: 10.3324/haematol.2019.238162. Haematologica. 2020. PMID: 33256379 Free PMC article. Clinical Trial.
71 results